Anteris Technologies Global Corp. 8-K

What Happened
Anteris Technologies Global Corp. (through its subsidiary Anteris Technologies Corporation) announced on April 28, 2026 that it elected to discontinue further development contributions under the Contribution and Stock Purchase Agreement dated April 18, 2023 with v2vmedtech, inc. The notice was given after completion of Stage 1 and during Stage 2 of the program. As required by the Agreement, Anteris will pay a $400,000 break fee to v2v and has no further obligation to fund additional development; the related Development Agreement will terminate upon payment of that fee.

Key Details

• Notice date: April 28, 2026; original Agreement date: April 18, 2023.
• Break fee: $400,000 payable to v2v to support continued development of the technology.
• Ownership outcomes: v2v’s initial shareholders may either (a) acquire all of Anteris’ equity in v2v for an amount equal to Anteris’ aggregate contributions to date, or (b) reduce Anteris’ equity to a capped minority percentage per the Agreement. v2v has not yet indicated which option it will choose.
• Effect on agreements: The Company’s obligation to fund further development ends, and the Development Agreement will terminate once the $400,000 is paid.

Why It Matters
This action ends Anteris’ future cash commitments under the v2v development deal and limits further funding obligations, with a one-time $400k cash outlay required. Depending on v2v’s shareholders’ election, Anteris could lose or see its equity stake reduced in v2v, which would affect any future upside from that asset. Anteris states it does not expect the discontinuation and termination to have a material adverse effect on its consolidated financial position or liquidity. The filing also contains standard forward‑looking statements and associated cautions.